Bridget Franciose
Nurse Practitioner · Kennebunk, MENPI 1801846563
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $363 of the $443 with a category attached, or 81.9%. 10 manufacturers reported payments, led by Daiichi Sankyo Inc. at 33.7% of the total. Among nurse practitioner clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 19 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$149
- Seagen Inc.$106
- Incyte Corporation$56
- Novocure Inc.$28
- Amgen$23
- Novartis$18
- plus $63 from 4 others
What the payments were for
- Food & beverage$36382%
- Education$8018%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 6 | $149 |
| Seagen Inc. | 3 | $106 |
| Incyte Corporation | 3 | $56 |
| Novocure Inc. | 1 | $28 |
| Amgen | 1 | $23 |
| Novartis | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Beigene USA, Inc. | 1 | $14 |
How this compares
$443 in reported general payments places this provider in the 90th percentile of 740 nurse practitioner providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 48 | $45,637 |
| Fentanyl | 97 | $10,097 |
| Morphine Sulfate ErMorphine Sulfate | 196 | $6,734 |
| Oxycodone Hcl | 216 | $5,418 |
| Methadone Hcl | 141 | $3,396 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 83 | $2,891 |
| Hydromorphone Hcl | 101 | $2,717 |
| Gabapentin | 73 | $1,676 |
| Methylphenidate Hcl | 44 | $1,340 |
| Morphine Sulfate | 38 | $1,196 |
| Olanzapine | 54 | $1,183 |
| Mirtazapine | 50 | $936 |
| Pregabalin | 33 | $591 |
| Duloxetine Hcl | 22 | $286 |
| Alprazolam | 20 | $252 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Kennebunk
- Loretta HothersallKennebunk$2K
- Angela ReedKennebunk$1K
- Melanie CoganKennebunk$1K
- Amanda MagnoliWestbrook$113K
- Gisele CastonguayLewiston$26K
- Rachel Koransky-MatsonBangor$16K
- Denise ViekmanPortland$15K
- Kerri NeelYork$5K
- Mallory EvansYork$5K
- Karrie SweetPortland$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.